• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?

作者信息

Williams Isabella S C, Perera Sachin, Murphy Declan G, Corcoran Niall M, Bolton Damien M, Lawrentschuk Nathan

机构信息

Department of Urology, Royal Melbourne Hospital, Parkville, Vic., Australia.

Department of Surgery, University of Melbourne, Parkville, Vic., Australia.

出版信息

BJU Int. 2022 Nov;130(5):580-581. doi: 10.1111/bju.15860. Epub 2022 Aug 2.

DOI:10.1111/bju.15860
PMID:35879832
Abstract
摘要

相似文献

1
Active surveillance versus enzalutamide for low-risk prostate cancer - was it really a trial we needed?主动监测与恩杂鲁胺治疗低风险前列腺癌——这真的是我们需要的试验吗？
BJU Int. 2022 Nov;130(5):580-581. doi: 10.1111/bju.15860. Epub 2022 Aug 2.
2
Re: Active Surveillance Plus Enzalutamide Monotherapy vs Active Surveillance Alone in Patients with Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial.回复：低风险或中风险局限性前列腺癌患者中主动监测联合恩杂鲁胺单药治疗与单纯主动监测的比较：ENACT随机临床试验
Eur Urol. 2022 Nov;82(5):572. doi: 10.1016/j.eururo.2022.07.030. Epub 2022 Aug 9.
3
Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Eur Urol. 2024 Apr;85(4):397. doi: 10.1016/j.eururo.2023.11.022. Epub 2023 Dec 11.
4
Enzalutamide and leuprolide acetate in non-metastatic hormone-sensitive prostate cancer: the sooner the better?恩杂鲁胺与醋酸亮丙瑞林治疗非转移性激素敏感性前列腺癌：越早越好？
Future Oncol. 2024 Feb;20(4):163-166. doi: 10.2217/fon-2023-1019. Epub 2024 Feb 7.
5
Combination therapy with radium-223 and enzalutamide in castration-resistant prostate cancer.镭-223与恩杂鲁胺联合治疗去势抵抗性前列腺癌。
Clin Adv Hematol Oncol. 2021 Dec;19(12):764-766.
6
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer.发现C19-9作为一种新型的αvβ3非RGD抑制剂，用于克服去势抵抗性前列腺癌中的恩杂鲁胺耐药性。
Signal Transduct Target Ther. 2023 Feb 10;8(1):60. doi: 10.1038/s41392-022-01236-z.
7
Identification of Genes Required for Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells .鉴定去势抵抗性前列腺癌细胞中恩杂鲁胺耐药相关基因
Mol Cancer Ther. 2021 Feb;20(2):398-409. doi: 10.1158/1535-7163.MCT-20-0244. Epub 2020 Dec 9.
8
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.CARD 研究：卡巴他赛对比阿比特龙或恩杂鲁胺用于转移性去势抵抗性前列腺癌老年患者的疗效和安全性。
Eur Urol. 2021 Oct;80(4):497-506. doi: 10.1016/j.eururo.2021.06.021. Epub 2021 Jul 15.
9
Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.来自PREVAIL试验的恩杂鲁胺用于未经化疗的转移性去势抵抗性前列腺癌男性患者的五年生存预测及安全性结果
Eur Urol. 2020 Sep;78(3):347-357. doi: 10.1016/j.eururo.2020.04.061. Epub 2020 Jun 9.
10
Enzalutamide shows sustained overall survival improvement in patients with metastatic hormone-sensitive prostate cancer.
Cancer. 2023 Aug 1;129(15):2278. doi: 10.1002/cncr.34910.

引用本文的文献

1
Pathological Effects of Apalutamide in Lower-risk Prostate Cancer: Results From a Phase II Clinical Trial.阿帕鲁胺治疗低危前列腺癌的病理效应：来自 II 期临床试验的结果。
J Urol. 2023 Feb;209(2):354-363. doi: 10.1097/JU.0000000000003038. Epub 2023 Feb 1.